Bayer CropScience announces decision not to resume MIC production
Bayer CropScience was planning to start the MIC unit and begin transitional production of Temik® brand insecticide early this year, but uncertainty over delays has led the company to the conclusion that a restart of production can no longer be expected in time for the 2011 growing season.
The safety of the MIC plant, which was overhauled completely and technically modified during the past months, was confirmed again by a federal court-commissioned special expert report on the plant’s safety, which was delivered to the court. However, against the background of the continuing uncertainty regarding the timing of resumption of production, the company needed to make a decision.
“This was a very difficult decision, particularly as our employees did everything possible to ensure the operational safety of our newly-constructed MIC unit during the remaining production period”, said Achim Noack, Member of the Board of Management of Bayer CropScience. “Our business case was based on our ability to supply the market needs beginning in 2011, and with the recent delays, that plan is no longer economically viable.”
Following a 2010 agreement with the U.S. Environmental Protection Agency, Bayer CropScience agreed to phase-out Temik® and had timed production to end in 2012, to allow for an orderly market exit and meet immediate customer needs. This basic conclusion was based on a number of factors, with both strategic and economic considerations, and is fully in line with Bayer CropScience’s global strategy to focus on delivering innovative solutions to modern agriculture and replacing older compounds in its portfolio, including WHO Class I products.
Other news from the department manufacturing
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.